RAAS Inhibitors Show Benefits in Pediatric CKD Vs. CCBs

Why It Matters

The findings support RAAS inhibitors as the preferred first‑line antihypertensive for pediatric CKD, potentially reshaping treatment guidelines and improving long‑term kidney outcomes for a vulnerable population.

Key Takeaways

• RAAS inhibitors cut dialysis/transplant risk by 42% vs CCBs.
• Adjusted HR 0.67 for composite kidney outcome with RAAS therapy.
• RAAS users achieved better BP control; 29% above 90th percentile.
• Overall adverse events lower on RAAS (HR 0.82), but hypotension higher.
• Nonglomerular CKD showed greatest benefit, HR 0.53 for dialysis.

Pulse Analysis

Pediatric chronic kidney disease carries a high risk of cardiovascular complications and premature kidney‑replacement therapy. Hypertension is a key driver of disease progression, and clinicians traditionally choose between RAAS blockade—often favored for its renoprotective effects—and calcium‑channel blockers, which are easier to manage. Yet robust head‑to‑head data in children have been scarce, leaving practitioners to rely on adult studies or limited pediatric trials. This evidence gap has contributed to variability in prescribing patterns across pediatric nephrology units.

The recent JAMA Pediatrics analysis leveraged the PRESERVE electronic‑health‑record cohort, encompassing 1,757 RAAS‑treated and 1,005 CCB‑treated patients from 2009‑2020. Using target‑trial emulation, the investigators adjusted for demographic and clinical confounders, revealing a 42% reduction in the hazard of initiating dialysis or transplant for RAAS users (adjusted HR 0.58). A composite endpoint—including ≥50% eGFR decline—also favored RAAS therapy (aHR 0.67). Blood‑pressure control improved markedly, with only 29% of RAAS patients spending time above the 90th percentile versus 39% on CCBs. Safety signals were reassuring: overall adverse events were 18% lower, though hypotension occurred more frequently, underscoring the need for vigilant monitoring.

For clinicians, the study delivers actionable guidance: RAAS inhibitors should be considered first‑line for most pediatric CKD patients, especially those with nonglomerular disease where the benefit was strongest (aHR 0.53 for dialysis). While the regimen demands regular labs for creatinine, potassium, and growth parameters, the long‑term kidney‑preserving advantage outweighs these logistical challenges. Payers and guideline committees may soon reflect these data, prompting broader insurance coverage for ACE inhibitors and angiotensin‑II receptor blockers in children. Future research should explore optimal dosing strategies, the role of combination therapy, and long‑term outcomes beyond two years to solidify the therapeutic paradigm.